Table IV.
General characteristics and clinical data of the AL patients and healthy individuals.
| Variables | ALL 111 (75.51) |
AML 36 (24.49) |
Healthy individuals 100 (100) |
P-valueb |
|---|---|---|---|---|
| Age (years, mean ± SD) | 7.73±4.91 | 8.02±4.79 | 10.21±5.53 | 0.002d |
| No. of leukocytes/mm3 | 19,700 (4,700–42,900)a | 34,550 (9,350–68,000)a | 8,000 (7,000–9,000)a | <0.001d |
| Gender | ||||
| Female | 41 (36.94) | 14 (38.89) | 47 (47.00) | 0.317 |
| Male | 70 (63.06) | 22 (61.11) | 53 (53.00) | |
| Status of participants | ||||
| Alive | 42 (37.84) | 13 (36.11) | 100 (100.00) | 1.00c |
| Deceased | 69 (62.16) | 23 (63.89) | - | |
| Risk by age and leukocytes at diagnosis | ||||
| Low-risk (1–10 years and <50,000 leukocytes/mm3) | 48 (43.24) | 12 (33.33) | - | 1.00c |
| High-risk (<1 and >10 years and >50,000 leukocytes/mm3) | 63 (56.76) | 24 (66.67) | - | |
| Relapse during treatment | ||||
| No | 40 (36.04) | 17 (47.22) | - | |
| Yes | 71 (63.96) | 19 (52.77) | - | 0.244c |
| Immunophenotype | ||||
| B-lineage | 93 (83.78) | - | - | - |
| T-lineage | 11 (9.91) | - | - | |
| B/T-lineage | 7 (6.31) | - | - | |
| FAB classification | ||||
| L1 | 93 (83.78) | - | - | - |
| L2 | 18 (16.22) | - | - | |
| M0 | - | 10 (27.77) | - | |
| M1 | - | 14 (38.89) | - | - |
| M2 | - | 6 (16.67) | - | |
| M3 | - | 6 (16.67) | - | |
| Chromosomal translocations | ||||
| ETV6-RUNX1 [t(12;21)] | 1 (0.90) | - | - | |
| BCR-ABL [t(9;22)] | 7 (6.31) | - | - | |
| AML1-ETO [t(8;21)] | - | 3 (8.33) | - | |
| CBFB-MYH11 [inv(16)] | - | 0 (0.00) | - | - |
| Negative | 64 (57.66) | 22 (61.11) | - | |
| Not determined | 39 (35.13) | 11 (30.56) | - | |
| miR-24 levels | 0.84 (0.21–2.54)a | 4.22 (2.08–8.22)a | 1.25 (1.09–1.61)a | <0.001d |
Data are expressed as n (%) unless indicated otherwise;
a
median (percentiles 25–75).
b
Obtained by the Chi-square test.
c
p-value obtained between patients with ALL and AML.
d
Significant p<0.05.
AL, acute leukemia; ALL, acute lymphoblastic leukemia AML, acute myeloid leukemia.